NICE and SMC recommend Shionogi's Mulpleo for thrombocytopenia

12 December 2019

The UK’s National Institute for Health and Care Excellence (NICE) and Scottish Medicines Consortium (SMC) have published positive appraisals recommending the use of Mulpleo (lusutrombopag) by the National Health Service (NHS) in England, Wales and Scotland for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) undergoing planned invasive procedures, Japanese drug major Shionogi (TYO: 4507).

These two recommendations are based principally on evidence from L-PLUS 18 and L-PLUS 29, two multicenter, randomized, double-blind, parallel-group, placebo-controlled, Phase III studies where 312 patients with CLD, severe thrombocytopenia with a platelet count of <50,000/µL and a scheduled invasive procedure received either lusutrombopag or placebo once daily for up to seven days. Lusutrombopag met the pre-specified primary endpoint and all key secondary endpoints with statistically-significant results.

Lusutrombopag is currently available in Japan and the USA, where it is marketed under the brand name Mulpleta.

No current treatments available

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK